Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) reported preliminary, unaudited results for Q4 and full year 2025 showing strong growth driven by molecular profiling. For Q4 2025, total revenue was approximately $281 million (+116%), including ~$270 million from Molecular Profiling (with ~$81 million prior-period true-ups), and ~52,700 clinical therapy selection cases (+20%). For full year 2025, total revenue was approximately $800 million (+94%), including ~$755 million from Molecular Profiling (with ~$33 million prior-year true-ups), and ~199,300 cases (+22%). Preliminary cash and marketable securities were ~$802 million as of Dec 31, 2025. Results remain unaudited and subject to change; final results expected with the late-February 2026 earnings release.
Positive
- Full year revenue approximately $800M (+94%)
- Q4 revenue approximately $281M (+116%)
- Molecular Profiling revenue ~$755M for 2025
- Completed ~199,300 clinical therapy selection cases (+22%)
- Preliminary cash and securities ~$802M as of Dec 31, 2025
Negative
- Results are preliminary and unaudited, subject to change
- Large prior-period true-ups: $81M Q4 and $33M year
- Molecular Profiling accounts for ~94% of 2025 revenue concentration
News Market Reaction – CAI
On the day this news was published, CAI declined 10.21%, reflecting a significant negative market reaction. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $873M from the company's valuation, bringing the market cap to $7.67B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CAI gained 0.92% ahead of strong preliminary 2025 results, while key biotech peers were mixed: MRNA appeared in momentum scanners (up ~4.02%), with MDGL and ROIV down and HALO, VRNA modestly up. This points to a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Conference appearance | Neutral | -2.1% | Announcement of presentation and Q&A at J.P. Morgan Healthcare Conference. |
| Dec 19 | Alliance expansion | Positive | +0.3% | Providence Swedish Cancer Institute joins Caris Precision Oncology Alliance. |
| Dec 16 | Pharma collaboration | Positive | +3.4% | Multi-year collaboration with Genentech for novel oncology target discovery. |
| Dec 04 | Scientific presentations | Positive | +3.0% | Plan to showcase 19 multimodal and AI-driven studies at SABCS 2025. |
| Dec 02 | Alliance expansion | Positive | +0.2% | UAMS Winthrop P. Rockefeller Cancer Institute joins Precision Oncology Alliance. |
Recent news has generally been followed by modestly positive price reactions, especially for collaborations and scientific/Alliance updates.
Over the past months, CAI highlighted multiple strategic and scientific milestones. In early Dec 2025, the Precision Oncology Alliance expanded further, and the company showcased 19 studies across seven breast cancer subtypes at SABCS. A multi-year collaboration with Genentech announced on Dec 16, 2025 included potential milestone payments up to $1.1 billion. Alliance additions on Dec 2 and Dec 19 grew its network of centers, while the Jan 2026 J.P. Morgan conference appearance underscores ongoing investor outreach, into which today’s preliminary 2025 results fit as a financial update.
Market Pulse Summary
The stock dropped -10.2% in the session following this news. A negative reaction despite strong preliminary results could echo past instances where solid earnings updates were followed by volatility. The release highlights full‑year revenue of $800M and case growth of 199,300, but emphasizes that figures are preliminary and unaudited. Any pullback might reflect profit‑taking after prior gains or caution around true‑up revenue and the pending final audit, rather than a clear shift in the underlying business trajectory.
Key Terms
molecular profiling medical
precision medicine medical
marketable securities financial
AI-generated analysis. Not financial advice.
Full year revenue growth of approximately
Fourth quarter 2025 preliminary unaudited financial results
For the three-month period ended December 31, 2025, as compared to the same period of 2024:
- Total revenue of approximately
$281 million 116% .- Consisting of approximately
$270 million $81 million $11 million
- Consisting of approximately
- Completed approximately 52,700 clinical therapy selection cases, an increase of approximately
20% and consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.
Full year 2025 preliminary unaudited financial results
For the twelve-month period ended December 31, 2025, as compared to the same period of 2024:
- Total revenue of approximately
$800 million 94% .- Consisting of approximately
$755 million $33 million $45 million
- Consisting of approximately
- Completed approximately 199,300 clinical therapy selection cases, an increase of
22% and consisting of approximately 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.
Preliminary unaudited cash, cash equivalents, restricted cash and marketable securities were approximately
"2025 was a breakthrough year for Caris as we became a public company and demonstrated the scale and impact of our comprehensive molecular profiling platform," said David D. Halbert, Founder, Chairman and CEO of Caris Life Sciences. "We continue to be focused on expanding clinical adoption, advancing a differentiated pipeline, and building the foundation for what we believe will be a new standard in precision medicine."
This announcement comes ahead of the Company's 1:30 Pacific time presentation today at the 44th Annual J.P. Morgan Healthcare Conference, which will include these results as well as additional business updates. Accompanying materials for this presentation will be posted, and live and replay webcasts will be available on our investor relations website at https://investor.carislifesciences.com.
Caris Life Sciences has not completed preparation of its financial statements for the fourth quarter or full year of 2025. The revenue, case volumes, and cash, cash equivalents, restricted cash and marketable securities presented in this release for the fourth quarter and the year ended December 31, 2025, are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete the review and preparation of our financial results. The company is in the process of completing its customary year-end close and review procedures as of and for the year ended December 31, 2025, and there can be no assurance that final results for this period will not differ from these estimates. During the preparation of Caris Life Sciences' consolidated financial statements and related notes as of and for the year ended December 31, 2025, the company's independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.
Caris Life Sciences plans to report its complete fourth quarter and full year 2025 financial results during its earnings call in late February 2026.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in
We intend to use the investor page of our website, https://investor.carislifesciences.com, as a distribution channel of material information about the Company and for complying with our disclosure obligations under Regulation FD. The information we post on our investor webpage may be deemed material. Accordingly, investors should subscribe to our investor alerts, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our substantial indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on November 5, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
Investor Relations:
IR@CarisLS.com
917.689.3511
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-preliminary-fourth-quarter-and-full-year-2025-results-302657929.html
SOURCE Caris Life Sciences
FAQ
What were Caris (CAI) preliminary Q4 2025 revenues and growth?
How much revenue did Caris (CAI) report for full year 2025?
What were Caris (CAI) molecular profiling revenues in 2025?
How many clinical cases did Caris (CAI) complete in 2025?
What cash position did Caris (CAI) report at Dec 31, 2025?
When will Caris (CAI) release final audited 2025 results?
